EUVIMEDEUVIMED entdecken
Open Access

Prognostic role of the innate immune signature CD163 and “eat me” signal calreticulin in clear cell renal cell carcinoma

Tadatsugu Anno, Nobuyuki Tanaka, Kimiharu Takamatsu, Kyohei Hakozaki, Ryohei Kufukihara, Yuto Baba, Toshikazu Takeda, Kazuhiro Matsumoto, Shinya Morita, Takeo Kosaka, Shuji Mikami, Hiroshi Nishihara und 2 weitere

Cancer Immunology, Immunotherapy · 2023

DOI: 10.1007/s00262-023-03369-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Tadatsugu Anno und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Keio University School of Medicine, Tokyo, 160-8582, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science, Takeda Science Foundation, Kobayashi Foundation for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansPrognosisCalreticulinImmunity, InnateCD163 Antigen

Stichwörter der Autor:innen

CD163CalreticulinEat me signalInnate immunityKidney cancerRenal cell carcinomaSurvivalTumor-associated macrophage

Substanzen

CD163 AntigenCalreticulin

Autor:innen und Institutionen

  • Department of Urology, Keio University School of Medicine, Tokyo, 160-8582, Japan.
  • Department of Urology, Keio University School of Medicine, Tokyo, 160-8582, Japan. urotanaka@keio.jp.
  • Department of Diagnostic Pathology, Keio University Hospital, Tokyo, 160-8582, Japan.
  • Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • Takeda Science Foundation
  • Kobayashi Foundation for Cancer Research
  • SGH Foundation for Cancer Research
  • Keio Gijuku Academic Development Funds
  • Princess Takamatsu Cancer Research Fund

Zitieren

APA

Anno, T., Tanaka, N., Takamatsu, K., Hakozaki, K., Kufukihara, R., Baba, Y., Takeda, T., Matsumoto, K., Morita, S., Kosaka, T., Mikami, S., Nishihara, H., Mizuno, R., & Oya, M. (2023). Prognostic role of the innate immune signature CD163 and “eat me” signal calreticulin in clear cell renal cell carcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03369-8

Vancouver

Anno T, Tanaka N, Takamatsu K, Hakozaki K, Kufukihara R, Baba Y, et al. Prognostic role of the innate immune signature CD163 and “eat me” signal calreticulin in clear cell renal cell carcinoma. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03369-8

BibTeX
@article{Anno2023,
  author = {Anno, Tadatsugu and Tanaka, Nobuyuki and Takamatsu, Kimiharu and Hakozaki, Kyohei and Kufukihara, Ryohei and Baba, Yuto and Takeda, Toshikazu and Matsumoto, Kazuhiro and Morita, Shinya and Kosaka, Takeo and Mikami, Shuji and Nishihara, Hiroshi and Mizuno, Ryuichi and Oya, Mototsugu},
  title = {Prognostic role of the innate immune signature CD163 and “eat me” signal calreticulin in clear cell renal cell carcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  doi = {10.1007/s00262-023-03369-8}
}
Kostenlos starten →